Exact Sciences SG&A Expenses 2010-2024 | EXAS

Exact Sciences sg&a expenses for the twelve months ending September 30, 2024 were $1.645B, a 1.99% increase year-over-year.

  • Exact Sciences annual sg&a expenses for 2023 were $1.62B, a 2.34% increase from 2022.
  • Exact Sciences annual sg&a expenses for 2022 were $1.583B, a 4.8% decline from 2021.
  • Exact Sciences annual sg&a expenses for 2021 were $1.663B, a 55.24% increase from 2020.

Exact Sciences SG&A Expenses 2010-2024 | EXAS

  • Exact Sciences annual sg&a expenses for 2023 were $1.62B, a 2.34% increase from 2022.
  • Exact Sciences annual sg&a expenses for 2022 were $1.583B, a 4.8% decline from 2021.
  • Exact Sciences annual sg&a expenses for 2021 were $1.663B, a 55.24% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$141B
Bristol Myers Squibb (BMY)$113.2B
Gilead Sciences (GILD)$112B
Vertex Pharmaceuticals (VRTX)$105.5B
CSL (CSLLY)$84.4B
Regeneron Pharmaceuticals (REGN)$76.6B
GSK (GSK)$68.6B
Argenex SE (ARGX)$39.6B
Alnylam Pharmaceuticals (ALNY)$30.7B
BioNTech SE (BNTX)$29.5B
Biogen (BIIB)$21.7B
Illumina (ILMN)$21.7B
BeiGene (ONC)$17.3B
Moderna (MRNA)$16.3B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14.7B
Incyte (INCY)$13.6B
BioMarin Pharmaceutical (BMRN)$12.8B
Sarepta Therapeutics (SRPT)$11.9B
Insmed (INSM)$11.7B
Bio-Techne Corp (TECH)$11.6B
Exelixis (EXEL)$10.3B
QIAGEN (QGEN)$10.2B
Vaxcyte (PCVX)$10.1B
Swedish Orphan Biovitrum (BIOVF)$10.1B
Intra-Cellular Therapies (ITCI)$10.1B
Bio-Rad Laboratories (BIO.B)$9.5B
Repligen (RGEN)$8.7B
Ascendis Pharma (ASND)$7.8B
Roivant Sciences (ROIV)$7.7B